利托那韦
THP1细胞系
发病机制
炎症
CD36
促炎细胞因子
巨噬细胞
免疫学
蛋白酶抑制剂(药理学)
肿瘤坏死因子α
药理学
医学
化学
生物
内科学
人类免疫缺陷病毒(HIV)
细胞培养
体外
病毒载量
生物化学
抗逆转录病毒疗法
受体
遗传学
作者
Weimin Guo,Mohsen Meydani,Angelo Azzi
标识
DOI:10.1096/fasebj.22.1_supplement.1103.9
摘要
Treatment with protease inhibitor (PI) drugs of HIV‐infected individuals has significantly increased their life span. However, one of the side effects of PI drugs is the development of premature atherosclerosis, whose molecular pathogenesis remains unclear. Earlier, we have reported that α‐tocopherol (α‐T) normalizes CD36 overexpression and reduces oxLDL uptake in THP‐1 cells. Since inflammation is a major player in the pathogenesis of atherosclerosis, we hypothesize that PI drugs, such as ritonavir, increase pro‐inflammatory cytokines synthesis and that α‐T supplementation counteracts this effect by suppressing pro‐inflammatory cytokines synthesis. Here, we report that after differentiating THP‐1 cells to macrophages, ritonavir treatment (10μg/mL) significantly increased expression of pro‐inflammatory cytokines, IL‐6, MCP‐1 and IL‐8, both at mRNA and protein levels. This effect of ritonavir was significantly suppressed by treatment of THP‐1/macrophages with 50μM α‐T. Our data suggest that supplemental α‐T may suppress ritonavir‐induced pro‐inflammatory cytokines in HIV‐infected individuals. (Supported by USDA agreement #58‐1950‐7‐707)
科研通智能强力驱动
Strongly Powered by AbleSci AI